WE AIM TO DEVELOP INNOVATIVE THERAPIES THAT TARGET HIGH UNMET MEDICAL NEEDS IN ONCOLOGY AND BACTERIAL INFECTIONS.
We develop for patients
For 40 years we have been committed to improving patient lives. With the heritage of our successful two standard-of-care therapies for prostate & colorectal cancer, we relentlessly aspire to identify and develop innovative treatments in both oncology and bacterial infections.
Discover our pipeline from discovery to phase III in oncology and bacterial infections
Together we can establish tomorrow’s standard of care! Driven by the ambition to cure, we are always seeking partners who share the same desire to bring new innovative solutions to patients’ unmet needs. Discover our partnering opportunities
Naratuximab emtansine (Debio 1562), an antibody-drug conjugate (ADC) targeting CD37, is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin’s lymphomas (NHL). Naratuximab emtansine (Debio 1562) demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with rituximab. The product is currently in phase IIb in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status